As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

Women frequently have more easily overlooked symptoms of ADHD, leading many to go undiagnosed or misdiagnosed until adulthood.

New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom managementROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals ...

Supernus is currently reviewing the details of these Notice Letters and intends to vigorously enforce its intellectual property rights relating to Qelbree. The U.S. Food and Drug Administration’s ...

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medtronic (MDT – Research Report), 908 Devices (MASS – Research Report) and Su ...

As it continues to ramp up sales of its attention-deficit/hyperactivity disorder (ADHD) drug Qelbree, Supernus Pharmaceuticals is getting Busy to raise awareness of ...

May 20, 2025 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mom, Busy Philipps, is stepping into an important new role as 'Ms. Represented' in partnership with Supernus Pharmaceuticals for a new ...

Busy Philipps partners with Supernus Pharmaceuticals to launch a campaign addressing ADHD in women, sharing her personal journey with Qelbree. Actress Busy Philipps has partnered with Supernus ...

Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 4.14M to 3.97M. This put 10.76% of the company's publicly available shares short.

ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...